Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Toronto Stock Exchange Reviewing GeneNews' Eligibility for Continued Listing

Toronto Stock Exchange Reviewing GeneNews' Eligibility for Continued Listing

Jan 19, 2016
|
staff reporter

NEW YORK (GenomeWeb) – Canadian molecular diagnostics company GeneNews announced today that it has received notice that the Toronto Stock Exchange is reviewing its eligibility to remain listed on the TSX. GeneNews has 60 days to show that it is in compliance with the continued listing requirements of the exchange.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Areas of Limited Testing

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

Clouded 'Crystal Ball'

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

Million a Day

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

Science Papers Trace Drivers of Metastasis; Genetic Analysis of Stone, Bronze Age Eastern Europeans

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.

What's Popular?

In Business News

  1. Illumina Wins UK Patent Infringement Suit Against BGI, Affiliates

  2. Ancestry Shutters Health Offering, Raising Questions About Future of Consumer Genomics

    Premium

  3. People in the News: New Appointments at Foundation Medicine, Sophia Genetics, Circulogene; More

  4. Lucira Health Files for $115M IPO

  5. Microba, University of Queensland Partner to Study Gut Microbiome in Parkinson's Disease

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.